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STUDY PROTOCOL Open Access
Efficacy and Feasibility of Pain
management and Patient Education for
Physical Activity in Intermittent claudication
(PrEPAID): protocol for a randomised
controlled trial
Ukachukwu O. Abaraogu1,2* , Philippa M. Dall3, Julie Brittenden4,5†, Wesley Stuart4, Garry A. Tew6,
Jon Godwin7 and Christopher A. Seenan3†
Abstract
Background: Physical activity (PA) improves functional capacity and quality of life and provides secondary prevention
benefits in individuals with peripheral arterial disease (PAD) and intermittent claudication (IC). However, pain and patient
lack of knowledge are key barriers to the uptake of, and adherence to, PA recommendations. This trial will test the
efficacy and feasibility of a non-invasive pain management intervention with and without patient education to improve
PA in individuals with PAD and IC.
Methods: This is a randomised, controlled assessor-blinded feasibility trial with four parallel groups. Eighty adults with
PAD and IC will be randomly assigned 1:1:1:1 to Active TENS (transcutaneous electrical nerve stimulation), Placebo TENS,
Active TENS + Patient education or Placebo TENS + Patient education groups. All groups will continue to receive usual
care over the intervention period. Participants randomised to Active TENS will receive a TENS device (preset at 120 Hz,
200 μs) and will be instructed to use the device daily at home or elsewhere for 6 weeks with a patient-determined
intensity of “strong but comfortable”. Placebo TENS group participants will receive the same model of TENS device and
instructions for use as those in the active group, except that the stimulation dose will be safely altered to produce non-
therapeutic, ineffective stimulation. Participants randomised to patient education will receive a one-off 3-h workshop of
structured group education (four to five persons in each group) and three sets of twice-weekly phone calls. Efficacy
outcomes will be assessed at baseline, after 6 weeks of intervention and at 3months follow-up. Absolute claudication
distance using the Gardner treadmill protocol will be assessed as the primary outcome. Secondary outcomes will assess
initial claudication distance, daily PA and patient-reported outcomes including quality of life, pain self-efficacy, depression,
disease perception and walking impairment pain intensity and quality. Feasibility outcomes will assess rates of
recruitment, retention and adherence. Focus groups with participants at the end of the trial will explore the acceptability
of the interventions.
(Continued on next page)
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Discussion: This trial will determine the efficacy and feasibility of using a low-cost, CE-marked non-invasive pain
management modality delivered with or without a patient-centred education intervention to improve PA in individuals
with PAD and IC.
Trial registration: ClinicalTrials.gov, NCT03204825. Registered on 2 July 2017.
Keywords: Peripheral arterial disease, Transcutaneous electrical nerve stimulation, Exercise, Physical activity, Patient-
centred care, Behavioural change therapy, Intermittent claudication
Background
Peripheral arterial disease (PAD) affects 2.7 million people
in the UK [1]. The most common symptom that patients
experience is intermittent claudication (IC), which is pain
in the buttock, calf or thigh precipitated by exercise and
relieved by rest [1]. The underlying cause of PAD is ath-
erosclerosis, which leads to arterial stenosis and inad-
equate blood flow and tissue oxygen delivery during
exercise [2–5]. Given the diffuse nature of atherosclerosis
and the involvement of other arterial beds, patients with
PAD and IC have a three to four times increased mortality
compared to age and sex matched controls [6]. In addition
IC has a major negative impact on patients’ mobility and
quality of life [7, 8].
Patients with symptomatic PAD should receive the
same secondary prevention management as patients with
symptomatic coronary artery disease [9]. Improving daily
physical activity (PA) is particularly important in individ-
uals with IC, as lower PA levels have been recognised as
a strong predictor of increased morbidity and mortality
in this population [10]. Current National Institute for
Health and Care Excellence (NICE) guidelines recom-
mend the use of supervised exercise programmes,
encouraging patients “to exercise to the point of max-
imal pain”, as first line treatment [11]. However, whilst
supervised exercise programmes lead to a significant im-
provement in the absolute walking distances of patients
with IC on a treadmill, it is unclear if this is sustained or
leads to improvement in daily PA [12]. Furthermore, due
to the resources required to deliver the recommended
3-month exercise programme (30–45 min three times
weekly), supervised exercise programmes are not always
routinely available to UK National Health Service (NHS)
patients. In addition, time and travel challenges (com-
pounded by background mobility issues) including costs
tend to lead to low patient uptake and high attrition
rates [13]. Therefore, investigating the feasibility of using
low-cost, patient-centred interventions that can support
increased PA is warranted.
Lack of self-efficacy, attributed to poor understanding of
the disease and uncertainty regarding the importance of ex-
ercise, has been shown to be a major barrier to exercise up-
take in this population [14]. Also, for patients with IC to
maximise the benefits of improved walking ability and
secondary prevention, they are recommended to exercise
beyond the point when pain occurs, which represents an-
other barrier to engagement in PA [15]. These barriers to
pain and lack of knowledge underscore the importance of
including pain management and patient education compo-
nents in a low-cost, patient-centred intervention as key to
enhancing uptake and adherence to exercise recommenda-
tions in individuals with PAD/IC [15, 16].
Our group recently developed and piloted Structured
EDucation for Rehabilitation in Intermittent Claudica-
tion (SEDRIC) [17], a patient-centred education inter-
vention with the specific aim of educating patients with
IC about their condition, improving patient ownership
and promoting self-managed walking. We found that in
patients with IC (n = 14), treadmill walking distances
(30%) and quality of life (32%) improved from baseline
after 6 weeks of structured education. In addition, there
was a trend for patients to increase their daily PA (ap-
proximately 8% changes from baseline).
Similarly, we have demonstrated in an experimental
lower limb ischaemic pain model in healthy volunteers
(n = 28) that transcutaneous electrical nerve stimulation
(TENS), a low-cost, CE-marked non-invasive pain man-
agement device, significantly increased pain threshold,
tolerance and endurance compared to placebo TENS
[18]. Our extension proof-of-concept pilot study demon-
strated that TENS, when applied to patients with IC ex-
ercising on a treadmill (n = 40), significantly improved
absolute claudication distance (ACD) by 40% above pla-
cebo levels [19]. We have not assessed the ability of
TENS to improve ACD when used during daily life.
Although patient-centred education (SEDRIC) and
TENS have both demonstrated potential to improve PA
in people with IC, the use of these components in com-
bination has not previously been evaluated. Therefore,
we do not know how potentially effective the combined
intervention will be compared to each of the individual
components. In addition, as part of the scaling process
for complex intervention development, it is important to
understand how the combined intervention can be feas-
ibly delivered amongst patients with PAD and IC within
the UK NHS. Equally key to informing the next stage of
the project is the acceptability of the intervention as a
whole or its individual components to patients with
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PAD and IC. Understanding these areas of uncertainty
will address an important literature gap related to inte-
grating two key components of pain management and
patient education modalities in a patient-centred inter-
vention to increase PA in individuals with PAD and IC.
To address these areas of uncertainty, we are under-
taking a 2 × 2 factorial, assessor-blinded, parallel-group,
placebo-controlled randomised trial of a Pain manage-
ment and Patient Education for Physical Activity in
Intermittent clauDication (PrEPAID) intervention. The
aim of the trial is to determine the efficacy and feasibility
of a TENS device used with or without a patient-centred
education programme to improve walking distances in
patients with PAD and IC. The following research ques-
tions will be addressed:
 What is the efficacy of the TENS device used with
or without a patient-centred education programme
to improve walking distances in patients with PAD
and IC?
 What is the feasibility (i.e. recruitment and retention
rates, adherence, safety, sample size for a definitive
trial) of conducting a definitive randomised
controlled trial (RCT) of TENS with and without
patient-centred education in patients with PAD and
IC?
 How acceptable are TENS and patient-centred edu-
cation as interventions on their own or in combin-
ation to patients with IC?
Methods/design
Trial design
The PrEPAID trial is a 2 × 2 parallel group (TENS versus
placebo TENS × patient education versus no additional
education) feasibility RCT to compare the use of TENS
against placebo TENS with and without a patient-centred
education programme. Permuted block randomisation will
be implemented to allocate patients to trial arms. The
study design including patient inclusion, measurement
and follow-up is shown in Fig. 1. Participants will be allo-
cated to one of four groups (n = 20 per group): Active
TENS, Active TENS + Patient education, Placebo TENS,
Placebo TENS + Patient education. Active TENS/placebo
and patient education interventions will be 6 weeks in
duration, and all participants will receive secondary pre-
vention therapy as recommended by NICE [11] including
advice to exercise (usual care). Outcomes for all partici-
pants will be assessed at two points (at baseline and after
6 weeks of education programme and/or TENS (active or
placebo). In addition, a subgroup of participants (those re-
cruited in the first 8 months of recruitment) will be
followed up 3months post the 6-week intervention. All
participants will be invited to attend a qualitative focus
group to be conducted after final follow-up.
The study protocol has been developed based on the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT). The SPIRIT figure (Fig. 2)
summarises the planned study conduct, review, report-
ing and interpretation. The completed SPIRIT checklist
is presented in Additional file 1. The Consolidated Stan-
dards of Reporting Trials (CONSORT) extension to pilot
and feasibility trials [20] and the Template for Interven-
tional Description and Replication (TIDieR) guidelines
[21] will be followed in reporting the final outcome of
this trial.
Trial settings
This study is hosted at the Clinical Research Facility
(CRF) of the Queen Elizabeth University Teaching Hos-
pital, Glasgow, UK. Patients attending the NHS Greater
Glasgow and Clyde vascular out-patient clinics will be
invited to take part.
Participant and eligibility criteria
Patients (aged 40–85 years) with a history of stable
IC and an ankle-brachial pressure index (ABPI) ≤ 0.9
will be recruited. Participants would be included if
they (1) have a clinical diagnosis of symptomatic
PAD including resting ABPI ≤ 0.9 in at least one leg;
(2) have had stable IC for ≥ 3 months; (3) have walk-
ing limited primarily by claudication; (4) are able to
exercise on a treadmill; (5) are able to read and
speak English to a level allowing satisfactory comple-
tion of the study procedures; (6) are able to provide
written informed consent for participation. The fol-
lowing exclusion criteria will be applied to patients:
(1) planned surgical or endovascular intervention for
PAD within the next 3 months; (2) critical limb is-
chaemia; (3) the presence of any absolute contraindi-
cations to exercise testing/training as defined by the
American College of Sports Medicine [22]; (4) previ-
ous experience of using TENS/ structured patient
education for PAD; (5) contraindications to TENS
(including epilepsy, dermatological conditions, in-
dwelling electrical pumps/pacemakers); (6) inability
to apply TENS independently (i.e. if a participant
fails to demonstrate ability to apply TENS after re-
ceiving training); (7) patients who require walking
aids including artificial limbs; (8) major surgery,
myocardial infarction or stroke/transient ischaemic
attack in the previous 6 months; (9) co-morbidities
that cause pain or limit walking to a greater extent
than IC (e.g. severe arthritis); (10) > 20% variation in
baseline ACD on treadmill, taken at 2 weeks apart;
(11) severe peripheral neuropathies above the ankle.
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Identification of participants and consent
Potential participants who are attending the vascular
out-patient clinics within NHS Greater Glasgow and
Clyde will be identified. They will be provided with a
participant information sheet (Additional file 2), and
contact details will be recorded on a study log. The
nurse or other members of the study team will contact
the patient, address any questions and arrange to meet.
At this meeting, assuming the participant fulfils the trial
eligibility criteria, informed consent (Additional file 3)
may be taken by the nurse, or if the patient wishes, he/
she will be given more time to consider participating in
the trial. Potential participants who have recently
attended the claudication clinic will also be contacted by
post and sent a brief outline of the study and the partici-
pant information sheet. They will be asked to return a
prepaid response slip stating whether they wish to be
contacted further regarding the study. If problems arise
with recruitment, then the option of using the Safe
Haven or primary care records to help identify patients
diagnosed with PAD and IC will be explored and appro-
priate approval obtained.
Randomisation
Eligible and consented patients who have completed the
baseline assessment and had ≤ 20% variation in ACD be-
tween the first and second visits will be randomly allo-
cated to the trial arms. A central and independent
randomisation facility (Internet-based randomisation
system, the Interactive Web Response (IWR) system)
will allocate the randomised therapy per patient. The
IWR system, which will be based at the Robertson
Fig. 1 Flowchart for participant identification, inclusion, study design, interventions, assessments and follow-up
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Institute University of Glasgow, will be available by web.
A simple fixed block design (FBD) will be used to allo-
cate patients to the groups. Randomisation outcome will
be sent by email only to researchers involved in adminis-
tering TENS and/or patient education. The outcome as-
sessors and data analyst will be blinded after assignment
to interventions.
Sample size
For the primary outcome measure, at 80% power and a
two-tailed 5% significance level, 16 participants per
group will allow detection of an effect size of 1.0 stand-
ard deviation of ACD in the Active TENS group com-
pared to the Placebo TENS control. Attrition rates in
our previous pilot studies ranged from 7.1 [17] to 10%
[19]. We will recruit 20 participants in each group,
allowing for 20% attrition, and therefore aim to recruit
80 participants. If this effect size were applied to our
separate pilot studies, this would provide the ability to
detect a change of 169 m (TENS) [19] or 322m (SED-
RIC) [17] in our primary outcome measure of ACD. In-
deed, in these studies, a sample size of 20 per group
(TENS) and 14 per intervention group (SEDRIC) was
sufficient to detect a significant difference in this out-
come measure.
Intervention procedures
Active TENS
Participants will be given a TENS device at the interven-
tion visit. They will be instructed to use the device daily
at home or elsewhere. They will be specifically advised
to use the device prior to or during a challenging walk
each day. Challenging walks could be for activities of
daily living or planned exercise. Those with bilateral
claudication will be advised to wear the device on the
worst limb and to alternate it as symptoms fluctuate.
The Active TENS group will receive high-frequency
TENS calibrated to 120 Hz, 200 μs, and will be free to
set the intensity to a “strong but tolerable” level [19]. An
MTR+ Dolito TENS machine (EME Services Ltd., Man-
chester, UK) will be used.
Treatment schedule Participants will be asked to wear
the active TENS device every day as often as they can
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure (numbers beside t represent weeks)
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when they are awake and switch it on when they are
standing/walking or about to engage in activity which
they anticipate would trigger their IC pain. They will be
instructed to switch it off after a maximum period of 1
h, for a rest period of at least 10–20min, and to repeat
this as often as warranted during daily activity.
Rationale for chosenTENS frequency In a proof-of-concept
study, high-frequency TENS (120Hz) was found to in-
crease the distance IC patients walked before reaching
pain tolerance, and that high-frequency TENS (compared
to low-frequency TENS) was more effective at prolonging
the time to reach pain threshold [19].
Attachment Patients will fit a TENS unit during wake
periods and daily activity using two self-adhesive carbon
rubber electrodes measuring 5 × 5 cm (StiMus® Hydrogel
Premium Self-Adhesive Electrodes, EME Services Ltd.)
attached to the TENS unit via the manufacturer’s leads.
The area of pain reported by the participant would de-
termine the electrode placement sites with the two elec-
trodes to be placed at least 2 cm apart. Before it is
provided to the patients for daily use, the TENS machine
will be calibrated with a digital oscilloscope and tested
manually by the research team.
Placebo TENS
Participants will receive the same model of TENS device
and instructions for use as those in the active group ex-
cept that the stimulation dose will be safely altered to
produce non-therapeutic, ineffective stimulation (6 mA).
This intensity setting will be locked off before the device
is provided to the participants, and they will not be able
to change it. This will allow the unit to be switched on
with the appearance of a working unit. For the purposes
of blinding, participants will be told that different dos-
ages of TENS are being tested and for some of these
dosages they might not feel anything even though the
device is working. Indeed the placebo effect has been re-
ported whilst using TENS in other conditions [23];
therefore, testing active TENS against placebo is recom-
mended. All TENS units will be calibrated, checked and
confirmed prior to being issued to participants. This
method of achieving placebo has been successfully used
in previous TENS trials [24–26].
Patient-centred education
The intervention for the groups receiving patient-centred
education will be adopted from the successfully piloted
SEDRIC study [17]: a one-off 3-h workshop of structured
group education (four to five persons in each group) and
three sets of twice-weekly phone calls. Two educators will
implement the session. Training for educators will involve
completion of the Diabetes Education and Self-Management
for Ongoing and Newly Diagnosed (DESMOND) [27] core
training; reading and demonstrating understanding of the
SEDRIC [17] curriculum; and completion of at least two
practice workshops that are quality assessed prior to deliver-
ing any sessions to patients. The aim of the structured edu-
cation is to modify patients’ illness beliefs and perceptions
about IC by educating them on disease pathology and man-
agement philosophy. After the workshop, each patient will
be supported to set goals for walking based around a ped-
ometer (Yamax SW-200 Digi-Walker pedometers) and daily
steps, and to develop an action plan regarding how these
goals will be met. Participants will be encouraged to repeat
this process for each new walking goal through
twice-weekly phone calls from the educators during which
the progress, barriers and challenges are further discussed,
and new walking goals will be set.
Trial schedule
Informed consent
Written informed consent shall be obtained from each
trial participant. The Research Nurse will explain the
exact nature of the study in writing (by provision of the
participant information sheet) and verbally, and will be
responsible for consenting the participants. Trial partici-
pants will be informed that they are free to withdraw
their consent from the study or study treatment at any
time. Participants will be asked to attend the CRF at
Queen Elizabeth University Hospital for a maximum of
six occasions.
Visit 1: first assessment visit
At the first visit, participants will be assessed for eligibil-
ity, and those eligible will be requested to consent for
further screening. Baseline outcome measurements will
be conducted including weight/height/heart rate/blood
pressure, ABPI, treadmill assessments, questionnaires
and a blood sample. Participants will be fitted with the
activPAL™ monitor and advised to wear it continuously
for 7 days. They will be given instructions on how to use
the activPAL and provided with a sleep diary to
complete during the duration of wearing the activPAL.
Visit 2: second assessment visit (usually within 2 weeks after
visit 1)
Participants will then attend for a second visit to
undergo a second treadmill test and to return the activ-
PAL and sleep diary. Only participants with ≤ 20% vari-
ation in ACD will continue in the trial. After this visit,
eligible participants will be randomised and given a date
on which to return for intervention (TENS/Placebo ±
Patient education) as applicable. Recruitment and ran-
domisation will be conducted in waves to allow groups
to be formed for the education session.
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Visit 3: intervention visit (within 3 weeks after
randomisation)
Participants attend the clinic to receive the TENS device
and training instructions for its daily use as required,
plus or minus the patient education per randomisation
group. Participants allocated to receive education will
undergo a structured group education session (four to
six persons per group) according to the SEDRIC proced-
ure [17]. Before the education session, participants allo-
cated to receive TENS will be provided with the device
and instructions for its use. The use of the device will
also be demonstrated, and patients will be shown how to
put it on and remove it. Participants will try out the de-
vice to be sure that they understand the procedure.
Visit 4: post-intervention assessment visit (end of the 6-
week intervention)
The outcome assessments and procedure followed in
visit 1 will be repeated including questionnaires, tread-
mill protocol, blood sample collection and fitting of
activPAL. The treadmill test will be conducted by inves-
tigators who are blinded to the participants’ group allo-
cation. Participants will be given a prepaid envelope in
which to return the activPAL monitor.
Visit 5: follow-up assessment visit (3 months post-
randomisation)
All participants recruited within the first 8 months of re-
cruitment will be invited to return for a 3 months
follow-up visit. The outcome assessments and procedure
followed in visits 1 and 4 will be repeated including ques-
tionnaires, treadmill protocol, blood sample collection and
fitting of activPAL. The treadmill test will be conducted
by investigators who are blinded to the participants’ group
allocation. Participants will be given a prepaid envelope in
which to return the activPAL monitor. We shall allow as-
sessment visit windows of ±2 weeks.
Visit 6: focus group visit (usually 1–3 weeks after the final
follow-up)
All participants will be invited to participate in a focus
group discussion. The discussion sessions, lasting 1 h, will
explore the acceptability of and satisfaction with the PrE-
PAID programme, components that were useful or not (in
terms of helping them with PA) and participants’ sugges-
tions for changes. Each focus group will consist of four to
six participants and will be facilitated by an independent
investigator. The number of focus groups to be conducted
will be determined by data saturation, and the sessions
will be audio-recorded and transcribed verbatim.
Laboratory tests
At visits 1, 4 and 5, 20 ml of blood will be taken from
rested subjects. The samples will be spun and stored as
per the standard operating procedure at the CRF at
Queen Elizabeth University Hospital for future analysis
of markers of angiogenesis and inflammatory response.
Participant retention and withdrawal
All reasonable efforts, within the CRF local standard
operating procedure, will be made to ensure optimum
participant engagement and to reduce study attrition.
However, the study involves an intention-to-treat ana-
lysis; therefore, if a patient does not apply the TENS or
attend the education class (if randomised to this arm),
he/she will continue to be followed up. Nonetheless, all
participants will have the right to withdraw from the
study at any stage. If the participant is willing to pro-
vide them, the reasons for withdrawal will be docu-
mented and any data already collected from that
participant will be analysed.
Outcome definitions
Efficacy outcomes
Measurements will be obtained at baseline, following the
6-week intervention and at 3 months follow-up. The pri-
mary efficacy outcome will be the treadmill-assessed ab-
solute claudication distance (ACD) (metres) using the
Gardner treadmill protocol [28].
Secondary efficacy outcomes will include initial claudi-
cation distance (metres) assessed by a treadmill exercise
using the Gardner treadmill protocol [28]. Daily PA will
be assessed via activPAL data outcomes: total number of
(1) steps; (2) upright events; (3) walking events; (4)
event-based claudication index (ratio of walking events
to upright events) participants undertake in a day [29].
Three days of activPAL data at each time point shall be
specified as minimum for including a patient’s activPAL
data in the efficacy analysis.
Other secondary outcomes will assess patient-reported
outcome measures. Disease-specific quality of life will be
as assessed using the Intermittent Claudication Ques-
tionnaire [30]. Generic quality of life via the General
Quality of Life Questionnaire (Short Form) [31], specif-
ically the total item score as well as the two main scores
(physical compound score and mental compound score),
will be analysed. Pain intensity will assessed with the vis-
ual analogue scale, whilst pain quality will be recorded
using the McGill Pain Questionnaire [32] 5 min after
every treadmill test. Average pain intensity in the past 7
days will be recorded using the visual analogue scale
[33]. Illness beliefs and psychosocial determinants of
health and behaviour will be recorded using the Brief Ill-
ness Perception Questionnaire [34], the Geriatric De-
pression Scale: Short Form [35] and the Pain
Self-Efficacy Questionnaire [36].
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Feasibility and acceptability outcomes
Regarding recruitment rates, reasons for non-eligibility
and non-recruitment of eligible patients will be recorded
via the study screening log. Participants’ retention
throughout the trial and reasons for withdrawal will be
documented. Adverse events in all groups will be moni-
tored, recorded, managed and followed up. Intervention
uptake (log of TENS use and attendance at education)
and acceptability of these interventions will be measured
via a questionnaire. TENS blinding fidelity will be assessed
via a TENS feedback questionnaire. Outcome completion
rate for all outcomes (number of days the activPAL is
worn, treadmill test completion, patient-reported outcome
measures at each outcome time point) will be assessed.
Acceptability of the intervention will be assessed through
focus group discussions at end of follow-up.
Recording and reporting of adverse events
We do not anticipate that the use of the CE-marked
TENS device will result in any serious adverse events. Par-
ticipants will be given prior information regarding the
reporting of adverse events and measures to take includ-
ing instructions to contact the research team via a dedi-
cated phone line. At each study visit, participants will be
specifically queried regarding the following adverse events
of special interest: any case of itching, skin breakdown,
mild electrical burn, other skin allergies or mild auto-
nomic responses. Reported related adverse events will be
documented in an applicable adverse event form.
Timing of outcome assessments
PA and patient-reported outcome measures will be
assessed at baseline, at the end of the 6-week intervention
(up to 2 weeks window) and 3months post-randomisation
(up to 2 weeks window). The recruitment, retention, out-
come completion, intervention uptake and attrition rates
will be assessed at the end of the study. Blinding and pa-
tients’ acceptability of TENS and ease of use will be
assessed at the point of patient exit from the study. Fur-
ther assessment regarding patients’ qualitative experience
of the intervention will be conducted after 3months
post-randomisation (up to 2 weeks window).
Statistics and data analysis
The Robertson Centre for Biostatistics, part of the Glas-
gow Clinical Trials Unit, a fully registered UK Clinical Re-
search Network (UKCRN) Clinical Trials Unit, will
manage the trial data. Statistical analysis will be led by the
study senior statistician (JG) at the Institute for Applied
Health Research, Glasgow Caledonian University; the stat-
istician is blinded to group allocation. Data analysis will be
performed following a detailed prespecified statistical ana-
lysis plan, which will be published separately.
In summary, an intention-to treat analysis will be per-
formed for the primary outcome on all randomised pa-
tients, except those who withdraw consent for the use of
their data [37, 38]. Baseline variables will be summarised
using descriptive statistics. Also, the feasibility, acceptabil-
ity, adverse events data and protocol and intervention ad-
herence data will be summarised by randomised group
and overall using descriptive statistics. Outcomes related
to experience and perception via focus groups will be ana-
lysed by framework analysis [39, 40].
Comparisons will be undertaken to investigate the feasi-
bility of studying the proposed outcomes for a definitive
trial and to calculate estimates for the likely effect sizes and
95% confidence intervals (CIs). To determine the feasibility
of conducting a definitive trial, inferential analysis will be
conducted at 95% CI, and the p value will be set at p < 0.05.
The change in the primary outcome will be compared be-
tween and within groups using Mann-Whitney U or Wil-
coxon signed-rank tests (or their parametric equivalents) as
applicable for between- and within-group comparisons. The
log-rank method for pooled samples or substrata will be im-
plemented where appropriate and when possible. Baseline
participants’ variability will be controlled for using the ana-
lysis of covariance. Also, other secondary efficacy analyses
will examine differences in the changes in activPAL out-
comes, initial claudication distance, patient-reported out-
comes and effect scores calculated using Mann-Whitney U
or Wilcoxon signed-rank tests (or their parametric equiva-
lents) as applicable for between- and within-group compari-
sons. Log-rank methods for pooled samples will be
conducted where indicated. For the statistical analysis the
software to be used is either SAS 9.2 for Windows (the SAS
Institute, Cary, NC, USA) or SPSS Version 22.
Data handling
Case report forms
An electronic case report form (e-CRF) will be used to
collect study data. The e-CRF will be developed by the
study Data Centre at the Robertson Centre for Biostatis-
tics, University of Glasgow, and access to the e-CRF will
be restricted, with only authorised site-specific personnel
able to make entries or amendments to the patients’
data. It is the responsibility of the research team to en-
sure completion and to review and approve all data cap-
tured in the e-CRF.
All data handling procedures will be detailed in a
study-specific data management plan. Data will be vali-
dated at the point of entry into the e-CRF and at regular
intervals during the study. Data discrepancies will be
flagged to the study site, and any data changes will be re-
corded in order to maintain a complete audit trail (rea-
son for the change, date the change was made, who
made the change).
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Record retention
To enable evaluations and/or audits from regulatory au-
thorities, the investigators will keep records, including
the identity of all participants (sufficient information to
link records), all original signed informed consent forms,
serious adverse event forms, source documents and de-
tailed records of treatment disposition in accordance
with the Good Clinical Practice guidelines, local regula-
tions or as specified in the Clinical Study Agreement,
whichever specifies a longer retention time. Data will be
retained at the Data Centre for a minimum of 5 years.
Trial management
This research falls under the auspices of the clinical gov-
ernance structure of Glasgow Caledonian University and
NHS Greater Glasgow and Clyde CRF. The project is
sponsored by Glasgow Caledonian University, and the
Glasgow Caledonian University Research and Develop-
ment Office will have responsibility for oversight, includ-
ing audit of adherence to protocol and research
governance standard operating procedures.
Trial Management Group
The trial will be coordinated from Glasgow Caledonian
University by the Trial Management Group. This will
consist of the co-investigators, NHS Greater Glasgow
and Clyde CRF Research Nurse, the Robertson Centre
for Biostatistics and the Glasgow Clinical Trial Unit. The
Trial Management Group will be responsible for the
overall management and completion of the project to
timescales. The role of the group is to monitor all as-
pects of the conduct and progress of the trial, ensure
that the protocol is adhered to and take appropriate ac-
tion to safeguard participants and the quality of the trial
itself. The group will meet bimonthly mainly via tele-
phone conferences.
Trial Steering Committee
The Trial Steering Committee will utilise the strengths
of diverse experts, including NHS Greater Glasgow and
Clyde service users. This will help ensure that the re-
search is relevant and accessible to a diverse audience.
The committee will have an independent chair. Specif-
ically, the committee will advise on the suitability of the
interventions for the population group and design and
participate in dissemination activities. The group mem-
bers consist of the Chief Investigators (CS and JB),
co-investigator (UA), two patient representatives, an ex-
pert in patient education interventions and PA behav-
iour change and an NHS management representative.
The steering group will meet four times spread
throughout the study with the aim of providing advice
from a broad perspective.
Protocol amendments
Any change in the study protocol will require an amend-
ment. Any proposed protocol amendments will be initi-
ated by the Chief Investigators following discussion with
the Trial Steering Committee, and any required amend-
ment forms will be submitted to the ethics committee,
funder, sponsor and NHS Greater Glasgow and Clyde Re-
search and Development for approval as appropriate to
their role. The Chief Investigators and the Trial Steering
Committee will liaise with the study sponsor to determine
whether an amendment is non-substantial or substantial.
All amended versions of the protocol will be signed by the
Chief Investigator and sponsor representative.
Insurance and indemnity
NHS indemnity is provided under the Clinical Negli-
gence and Other Risks Indemnity Scheme and the Glas-
gow Caledonian University indemnity insurance.
Study reports
An annual progress report will be submitted to the
funder, the Chief Science Office (CSO), Scotland, UK,
the first being submitted 6 months from the date that all
trial-related approvals are in place. Annual reports will
be submitted to the ethics committee and sponsor, with
the first submitted one year after the date that all
trial-related approvals are in place. Recruitment data
will, on a monthly basis, be uploaded to the UKCRN
Portfolio database (and agreed successor to the database)
through the mechanisms provided for the purpose, as
part of the CSO requirement. Also, updated information
on the outputs from the project shall be uploaded
through the e-VAL system, which is now accessed
through the ResearchFish website at https://researchfish.
com/user/login?destination=awards. A final project re-
port and other information and actions as required by
the CSO as part of the project completion will be avail-
able and completed to the satisfaction of the CSO by the
end of the funding period. Copies of all publications ori-
ginating from this trial shall be provided to the CSO.
The Chief Investigators and Project Management Group
will produce all reports. All statistical reports will be
produced by the Study Statistician from the Institute for
Applied Health Research, Glasgow Caledonian
University.
Participants’ data protection
The data obtained from participants will remain confi-
dential and stored securely at the Robertson Centre for
Biostatistics University of Glasgow. The data are held in
accordance with the Data Protection Act, which means
that we keep it safely and cannot reveal it to other
people without appropriate permission. The data held
on the database will not be identifiable. In addition, PA
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data and basic demographic data will be kept on a pass-
word protected database on a secure server at Glasgow
Caledonian University. The data held on the database
will not be identifiable. This information collected may
be used for further analysis by staff and students in the
School of Health and Life Sciences at Glasgow Caledo-
nian University at a later date.
Trial dissemination
The outcomes of the trials will be widely disseminated
in journals and at scientific conferences.
Discussion
Individuals with peripheral arterial disease (PAD) and
intermittent claudication (IC) are at high risk of cardio-
vascular events, hospitalisation and death [41–44]. En-
couraging physical activity (PA) in individuals with IC is
of both clinical and public health importance. Super-
vised exercise programmes are effective and are the rec-
ommended therapy to improve walking distances,
cardiovascular fitness and quality of life benefits in indi-
viduals with IC. However, supervised exercise pro-
grammes are not readily available to most patients with
PAD and IC, and, when available, the programmes rec-
ord low patient engagement and high attrition.
In two recent systematic reviews, we identified pa-
tients’ lack of disease understanding, uncertainty about
exercise and the claudication pain as important barriers
that prevent patients with PAD and IC from engaging in
walking exercise [45], contributing to worse disease ex-
perience [46]. The results of these reviews underscored
the importance of a self-management perspective to de-
velop an intervention that concomitantly manages pain
and educates patients about their disease pathology and
the rationale of walking as a way of encouraging patients
to adopt and adhere to the walking exercise recommen-
dation. We also identified important intervention com-
ponents through a series of systematic reviews, and we
have conducted a series of laboratory, proof-of-concept
and pilot studies underpinning both components of PrE-
PAID. We subsequently developed PrEPAID following
the Medical Research Council (MRC) framework for
complex interventions [47].
Whilst patient-centred education and TENs for pain
management have both individually demonstrated po-
tential to increase PA in individuals with PAD and IC,
the use of these components together has not been eval-
uated. In line with the MRC framework for complex
intervention development and evaluation, this trial will
demonstrate the feasibility and potential benefit of TENS
used with or without patient-centred education to im-
prove PA in individuals with PAD and IC. This is an im-
portant consideration, since the two components of the
intervention primarily target different important barriers
to walking in this population. Findings will also be im-
portant in refining and tailoring the next phase of the
intervention as well as in estimating sample size for the
full RCT.
Trial status
The study is ongoing at the time of submitting this
manuscript (December 2018). This trial was using
protocol version 2.0 (12 September 2017) at the time of
this submission. Recruitment started in the Queen
Elizabeth University Hospital on 17 May 2018 and is
expected to be completed on 17 July 2019. The trial
management committee manages and disseminates the
protocol amendments.
Additional files
Additional file 1: Completed SPIRIT checklist for PrEPAID trial. (DOC 382 kb)
Additional file 2: Participant information sheet for PrEPAID trial.
(DOCX 190 kb)
Additional file 3: Participant consent form for PrEPAID trial. (DOCX 217 kb)
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